Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Polynovo ( (AU:PNV) ) has issued an update.
PolyNovo Limited has appointed Bruce Peatey as the new CEO, effective December 1, 2025. With extensive experience in healthcare, medical devices, and biotechnology, Peatey brings valuable skills in managing quality and regulatory functions, strategic business development, and market expansion. His leadership is expected to drive PolyNovo’s growth into new markets and enhance its international presence, particularly in the outpatient sector. The company anticipates that Peatey’s expertise and established relationships in the industry will inform its strategic approach to distribution in the US and key international markets.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited is a company operating in the healthcare industry, focusing on medical devices and biotechnology. The company is known for delivering transformative solutions that improve patient outcomes globally and is currently expanding into the outpatient market and broadening its international presence.
Average Trading Volume: 3,456,110
Technical Sentiment Signal: Sell
Current Market Cap: A$946.5M
For detailed information about PNV stock, go to TipRanks’ Stock Analysis page.